查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1994194

克隆氏症治疗市场：全球市场按治疗方法、给药途径、分销管道和最终用户分類的预测——2026-2032年

Crohn's Disease Therapeutics Market by Therapy Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年克隆氏症治疗市场价值为 140 亿美元，预计到 2026 年将成长至 146.8 亿美元，复合年增长率为 5.90%，到 2032 年将达到 209.2 亿美元。

主要市场统计数据
基准年 2025 140亿美元
预计年份：2026年 146.8亿美元
预测年份 2032 209.2亿美元
复合年增长率 (%) 5.90%

对克隆氏症治疗市场进行全面概述，重点在于临床因素、未满足的需求和不断发展的治疗模式。

克隆氏症仍然是一种复杂多样的发炎性肠道疾病，给临床医生、保险公司和生命科学创新者都带来了挑战。过去十年，治疗方法已从广泛的免疫抑制疗法转向标靶生物製剂和小分子药物策略，旨在调节特定的免疫路径。因此，治疗方法决策越来越需要在疗效、长期安全性、免疫抗原性以及以患者为中心的因素（例如给药途径和治疗负担）之间取得平衡。因此，相关人员必须探讨临床疗效、便利性和安全性之间的相互作用如何影响治疗方法的采纳和持续使用。

变革性的变化正在重塑克隆氏症的治疗，包括新的作用机制、成功的临床试验、以患者为中心的治疗模式以及保险公司的发展趋势。

克隆氏症的治疗格局正在经历一场变革，这主要得益于生物製药特异性的提高、口服小分子药物的出现以及以患者为中心的医疗保健理念的日益普及。包括更具选择性的白细胞介素和整合素抑制剂在内的新型作用机制，正在改变人们对持续缓解和黏膜癒合的预期，而真实世界数据则进一步明确了它们相对于传统药物的地位。同时，製剂和给药方法的创新正在透过提供更方便的皮下给药方案和拓展口服製剂的适用范围，减轻患者的治疗负担。

评估 2025 年美国关税对治疗药物供应链、定价策略、临床试验机会和奖励的累积影响。

美国2025年实施的累积关税将为药品供应链、商业性定价策略以及更广泛的药品取得趋势创造新的商业环境。关税导致活性成分、生物製药成分、管瓶及相关耗材的投入成本增加，可能推高生产和分销成本。为此，製造商可能会重新评估对海外供应的依赖程度，并加快区域生产投资，并调整筹资策略以降低关税变化带来的风险。

对治疗药物的分类、给药途径、分销管道和最终用户途径如何影响治疗结果和商业策略进行細項分析。

对克隆氏症治疗市场的細項分析揭示了治疗分类、给药途径、分销管道和最终用户如何共同影响临床和商业性结果。根据治疗分类，市场可分为生物製剂、免疫抑制剂和小分子药物。生物製剂可进一步细分，包括整合素抑制剂（如维多珠单抗）、白细胞介素抑制剂（如利沙珠单抗和Ustekinumab单抗）以及TNF抑制剂（如Adalimumab、赛妥珠单抗和Infliximab单抗）。免疫抑制剂包括胺基甲基叶酸和硫嘌呤类药物，其中Azathioprine和Mercaptopurine是后者的亚类。小分子药物则以JAK抑制剂为主，託法替尼和Upadacitinib在监管方面和安全性特征上有差异。

从区域观点看美洲、欧洲、中东和非洲以及亚太地区的治疗方法的引进、法规结构、取得途径和商业性趋势。

区域趋势对于治疗创新如何惠及患者以及如何在不同的医疗保健系统中实施商业策略至关重要。在美洲，市场环境的特征是支付方结构分散、专科药房网络强大，以及高度成熟的商业性模式，这些都支持差异化的价值提案和基于结果的合约。相较之下，欧洲、中东和非洲（EMEA）地区的监管和报销环境则较为复杂，集中核准体系与国家层级的准入谈判以及不同的卫生技术评估（HTA）实务并存。因此，灵活的打入市场策略和可靠的本地证据至关重要。

该分析检验了克隆氏症治疗领域中竞争定位、开发平臺、策略联盟、生产规模和差异化等关键公司层面的见解。

克隆氏症治疗领域的企业级策略体现了产品组合多元化、定向研发投资和商业性合作的综合策略。领先的生物製药公司专注于差异化的作用机制，例如选择性白细胞介素调节和肠道特异性整合素阻断，同时也在投资生命週期策略，包括拓展适应症、开发替代製剂和联合治疗。同时，中型和专业生物技术公司则致力于透过生物标记主导的研发和精准医疗方法，在细分市场中占有一席之地，以满足尚未被满足的患者需求。

为指导克隆氏症治疗的临床开发、商业化、患者取得和供应的韧性，提出切实可行的优先建议。

克隆氏症治疗领域的领导企业应采取一系列优先行动，以协调临床开发、商业性化营运和患者可及性的关键需求。首先，设计临床计画时，应同时关注疗效终点和可操作的真实世界指标，以满足监管机构、付款者和临床医生的需求。这种双重关注强化了其在治疗流程中优先地位的合理性。其次，透过地理多元化和合约弹性优化供应链，降低关税和地缘政治因素造成的干扰，同时确保接受慢性治疗的患者能够获得持续的医疗服务。

采用综合混合方法的研究途径，结合专家访谈、系统性文献回顾、供应链检验和资料三角验证。

本执行摘要的调查方法融合了多种定性和定量方法，以确保研究结果的可靠性和可重复性。主要研究包括对临床意见领袖、支付方、专科药剂师和商业领袖进行结构化访谈，以了解他们对治疗结果、推广障碍和报销趋势的实际观点。除了这些直接意见外，我们还对同行评审的临床文献、监管文件和指南更新进行了系统性回顾，以检验作用机制和安全性讯号。

整合临床、商业性和政策影响，以帮助相关人员推进治疗方案和以病人为中心的护理路径。

总之，克隆氏症治疗领域的特点是治疗方法的快速进步、医疗服务模式的不断演变以及商业性趋势的转变，所有这些因素都要求产业和临床相关人员具备策略灵活性。虽然生物製药和口服小分子化合物特异性的提高正在拓展治疗选择，但它们的引入取决于其是否具有可证实的临床获益、安全性可控以及是否符合支付方的预期。同时，关税政策的变化和供应链的脆弱性等外部因素进一步增加了营运风险，这些风险必须得到积极应对。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章克隆氏症治疗市场（依治疗方法划分）

  • 生物製药
    • 整合素抑制剂
    • 白细胞介素抑制剂
      • 利沙珠单抗
      • Ustekinumab
    • TNF抑制剂
      • Adalimumab
      • 赛妥珠单抗
      • Infliximab
  • 免疫抑制剂
    • 胺基甲基叶酸
    • 硫嘌呤型
      • Azathioprine
      • Mercaptopurine
  • 低分子化合物

第九章克隆氏症治疗市场：依给药途径划分

  • 静脉
  • 口服
  • 皮下

第十章克隆氏症治疗市场：依通路划分

  • 医院药房
  • 零售药房
  • 专科诊所

第十一章克隆氏症治疗市场：依最终用户划分

  • 居家医疗设施
  • 医院
  • 专科诊所

第十二章克隆氏症治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章克隆氏症治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章克隆氏症治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国克隆氏症治疗市场

第十六章：中国克隆氏症治疗药物市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Arena Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • MorphoSys AG
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Theravance Biopharma, Inc.
  • UCB SA
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-1A1A064C0471

The Crohn's Disease Therapeutics Market was valued at USD 14.00 billion in 2025 and is projected to grow to USD 14.68 billion in 2026, with a CAGR of 5.90%, reaching USD 20.92 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.00 billion
Estimated Year [2026] USD 14.68 billion
Forecast Year [2032] USD 20.92 billion
CAGR (%) 5.90%

Comprehensive introduction to Crohn's disease therapeutics landscape emphasizing clinical drivers, unmet needs, and evolving treatment paradigms

Crohn's disease remains a complex, heterogeneous inflammatory bowel condition that challenges clinicians, payers, and life science innovators. Over the past decade therapeutic approaches have shifted from broadly immunosuppressive regimens to targeted biologic and small molecule strategies designed to modulate specific immune pathways. As a result, treatment decision-making increasingly balances efficacy with long-term safety, immunogenicity, and patient-centered considerations such as route of administration and treatment burden. Consequently, stakeholders must navigate a landscape where clinical efficacy, convenience, and safety profiles jointly influence adoption and persistence.

In parallel, healthcare systems are adapting reimbursement models, specialty pharmacy operations, and specialty clinic capabilities to support more personalized treatment algorithms. Real-world evidence initiatives and longitudinal registries are expanding understanding of treatment durability and comparative effectiveness, which in turn shape clinical guidelines and payer coverage. Given these dynamics, strategic planning for product development, market entry, and access requires integrated insights that marry clinical science with commercial realities. This executive summary synthesizes those critical dimensions to help decision-makers identify opportunities and risks within the therapeutic continuum for Crohn's disease.

Transformative shifts reshaping Crohn's disease care including novel mechanisms of action, trial successes, patient-centric delivery models, and payer dynamics

The therapeutic landscape for Crohn's disease is undergoing transformational shifts driven by advances in biological specificity, the emergence of oral small molecules, and a growing emphasis on patient-centric care delivery. Novel mechanisms of action, including more selective interleukin and integrin blockade, are changing expectations for sustained remission and mucosal healing, while real-world evidence continues to refine positioning versus legacy agents. At the same time, innovation in formulation and administration is reducing treatment burden through more convenient subcutaneous dosing and oral options that expand settings of care.

Concurrently, payers and providers are recalibrating access pathways to manage the cost and clinical complexity of newer agents. Value-based contracting, outcomes-based agreements, and specialty pharmacy integration are gaining traction as tools to align cost with observed clinical benefit. Moreover, safety signals and lifecycle management considerations are influencing label expansions and post-marketing requirements, which drive clinicians to adopt risk-management strategies. Taken together, these shifts are producing a more stratified pathway for patients where treatment selection reflects not only disease biology but also delivery preferences, safety tolerance, and system-level incentives.

Assessing the cumulative impact of United States tariffs in 2025 on therapeutics supply chains, pricing strategies, clinical access, and innovation incentives

The introduction of cumulative United States tariffs in 2025 introduces a new operating context for therapeutic supply chains, commercial pricing strategies, and broader access dynamics. Tariff-driven increases in input costs for active pharmaceutical ingredients, biologic components, vials, and ancillary supplies can raise manufacturing and distribution expenditures. In response, manufacturers may reassess offshore supply concentration, accelerate regional manufacturing investments, or revise sourcing strategies to mitigate exposure to tariff volatility.

From a commercial perspective, incremental cost pressures can complicate negotiations with payers and integrated delivery networks, prompting stronger emphasis on total cost of care and outcomes-based arrangements. In the short term, providers and specialty pharmacies may experience inventory and fulfillment stress as suppliers reorganize logistics to accommodate tariff-related constraints. Over the medium term, policy-induced cost differentials can incentivize local production, contractual hedging, and increased vertical integration among suppliers to protect margin and secure supply reliability.

Finally, the tariff environment has implications for innovation incentives. Higher trade barriers can raise the effective cost of bringing complex biologics and high-value small molecules to market in the US, thereby influencing clinical development prioritization and go-to-market sequencing. As a result, strategic planning must account for scenarios that blend procurement complexity with payer sensitivity and evolving manufacturing footprints.

Segmentation insights into how therapy classes, administration routes, distribution channels, and end-user pathways influence outcomes and commercial strategy

A segmentation-aware view of Crohn's therapeutics reveals how therapeutic class, route of administration, distribution channel, and end user jointly shape clinical and commercial outcomes. Based on therapy class, the market divides into Biologics, Immunosuppressants, and Small Molecules, with further granularity within biologics to include Integrin Inhibitors such as vedolizumab, Interleukin Inhibitors including risankizumab and ustekinumab, and TNF Inhibitors such as adalimumab, certolizumab, and infliximab. Immunosuppressants are represented by agents like methotrexate and thiopurines, the latter subgroup including azathioprine and mercaptopurine, while small molecules center on JAK inhibitors with tofacitinib and upadacitinib illustrating divergent regulatory and safety profiles.

In addition, the route of administration-intravenous, oral, and subcutaneous-meaningfully influences clinical adoption, site-of-care economics, and patient preference. Distribution channels from hospital pharmacies to retail pharmacies and specialty clinics create distinct access and dispensing models that affect continuity of care and reimbursement complexity. Finally, end users span home care settings, hospitals, and specialty clinics, each with different capabilities for monitoring, adherence support, and infusion infrastructure. When considered together, these segmentation dimensions indicate that targeted strategies must be tailored to the interplay of mechanism of action, delivery modality, channel logistics, and care setting to optimize uptake and long-term persistence.

Regional perspectives on therapeutic adoption, regulatory frameworks, access pathways, and commercial dynamics across Americas, EMEA, and Asia-Pacific

Regional dynamics are pivotal to how therapeutic innovations reach patients and how commercial strategies are executed across disparate health systems. In the Americas, markets are characterized by fragmented payer landscapes, strong specialty pharmacy networks, and a high degree of commercial sophistication that favors differentiated value propositions and outcomes-based contracting. By contrast, Europe, Middle East & Africa presents a heterogenous regulatory and reimbursement environment in which centralized approvals coexist with country-level access negotiations and diverse health technology assessment practices, requiring adaptive market access strategies and robust local evidence generation.

In the Asia-Pacific region, evolving regulatory harmonization, growing local manufacturing capabilities, and rapid adoption of digital health tools are accelerating access to both biologics and small molecules. Pricing pressures and increasing emphasis on cost-effectiveness are driving tiered launch sequencing and selective commercialization models. Across all regions, stakeholders must align clinical trial design, real-world evidence programs, and supply chain resilience to regional policy nuances and payer expectations. Ultimately, region-specific regulatory frameworks, distribution infrastructures, and patient management norms will determine the pace and shape of adoption for new Crohn's therapeutics.

Key company-level insights examining competitive positioning, R&D pipelines, strategic partnerships, manufacturing scale, and go-to-market differentiation in Crohn's therapeutics

Company-level strategies in Crohn's disease therapeutics reflect a mix of portfolio diversification, targeted R&D investment, and commercial partnerships. Leading biopharmaceutical organizations are concentrating on differentiated mechanisms such as selective interleukin modulation and gut-specific integrin blockade while investing in lifecycle strategies that include label expansions, formulation alternatives, and combination approaches. At the same time, mid-sized firms and specialized biotech companies are pursuing niche positioning through biomarker-driven development and precision medicine approaches to capture segments of the patient population with unmet needs.

Manufacturing scale and supply chain agility are increasingly central to competitive advantage, prompting strategic partnerships, contract manufacturing diversification, and regional footprint expansion. Commercial differentiation hinges on integrated services; companies that complement drug efficacy with patient support programs, hub services for specialty distribution, and digital adherence tools are better positioned to maintain persistence and reduce overall cost of care. In this evolving competitive landscape, partnerships and licensing deals can accelerate market entry and broaden clinical utility, while targeted M&A activity supports vertical integration where it bolsters supply security or accelerates access to proprietary technologies.

Practical and prioritized recommendations guiding clinical development, commercial execution, patient access, and supply resilience for Crohn's therapeutics

Leaders in the Crohn's therapeutics space should adopt a set of prioritized actions that align clinical development with commercial execution and patient access imperatives. First, design clinical programs that generate both robust efficacy endpoints and pragmatic real-world measures to satisfy regulators, payers, and clinicians; this dual focus improves the case for preferred placement in treatment algorithms. Second, optimize supply chains through geographic diversification and contractual resilience to reduce exposure to tariff-driven or geopolitical disruptions and to ensure continuity of care for patients on chronic therapy.

Third, develop comprehensive access strategies that combine value-based contracting with specialty pharmacy integration and digital patient support to maximize adherence and persistence. Fourth, tailor launch sequencing by channel and setting of care-recognizing that intravenous, subcutaneous, and oral modalities demand distinct operational approaches and reimbursement negotiations. Finally, invest selectively in companion diagnostics and biomarker research to support targeted use cases and to clear pathways for premium positioning where clinical differentiation is demonstrable. By prioritizing these actions, organizations can translate clinical promise into sustainable commercial performance while safeguarding patient access.

Comprehensive mixed-method research approach integrating expert interviews, systematic literature review, supply chain validation, and data triangulation

The research methodology underpinning this executive summary integrates multiple qualitative and quantitative approaches to ensure robust, replicable insights. Primary research included structured interviews with clinical thought leaders, payers, specialty pharmacists, and commercial leaders to capture frontline perspectives on therapeutic performance, adoption barriers, and reimbursement dynamics. These firsthand inputs were complemented by systematic review of peer-reviewed clinical literature, regulatory documentation, and guideline updates to validate mechanistic rationale and safety signals.

To strengthen reliability, the analysis incorporated supply chain validation through vendor mapping and distributor interviews, as well as triangulation across data sources to reconcile discrepancies and surface consistent patterns. Scenario analysis was used to stress-test strategic assumptions-particularly around tariff impacts, route-of-care shifts, and payer contracting innovations-so that recommendations reflect plausible operational contingencies. Finally, editorial synthesis prioritized clarity and actionable relevance for decision-makers, with transparent note of limitations where primary evidence is still evolving, thereby enabling informed use of the intelligence in strategic planning.

Conclusion synthesizing clinical, commercial, and policy implications for stakeholders aiming to advance therapeutic options and patient-centric care pathways

In conclusion, the Crohn's disease therapeutics landscape is characterized by rapid therapeutic innovation, evolving care delivery models, and shifting commercial dynamics that together demand strategic agility from industry and clinical stakeholders. Advances in biologic specificity and oral small molecules are expanding treatment options, but adoption will pivot on demonstrable real-world benefits, manageable safety profiles, and alignment with payer expectations. At the same time, external factors such as tariff policy changes and supply chain fragility add layers of operational risk that must be proactively managed.

Therefore, stakeholders should pursue an integrated approach that links clinical differentiation with pragmatic access strategies, resilient manufacturing and distribution, and evidence generation tailored for local health system needs. When executed thoughtfully, such an approach can accelerate appropriate patient access, support sustainable commercial returns, and foster innovation that meaningfully improves long-term patient outcomes. These synthesized implications provide a strategic foundation for teams seeking to navigate near-term disruptions while positioning for enduring success in Crohn's therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Crohn's Disease Therapeutics Market, by Therapy Class

  • 8.1. Biologics
    • 8.1.1. Integrin Inhibitors
    • 8.1.2. Interleukin Inhibitors
      • 8.1.2.1. Risankizumab
      • 8.1.2.2. Ustekinumab
    • 8.1.3. TNF Inhibitors
      • 8.1.3.1. Adalimumab
      • 8.1.3.2. Certolizumab
      • 8.1.3.3. Infliximab
  • 8.2. Immunosuppressants
    • 8.2.1. Methotrexate
    • 8.2.2. Thiopurines
      • 8.2.2.1. Azathioprine
      • 8.2.2.2. Mercaptopurine
  • 8.3. Small Molecules

9. Crohn's Disease Therapeutics Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Crohn's Disease Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Retail Pharmacies
  • 10.3. Specialty Clinics

11. Crohn's Disease Therapeutics Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Crohn's Disease Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Crohn's Disease Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Crohn's Disease Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Crohn's Disease Therapeutics Market

16. China Crohn's Disease Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Amgen Inc.
  • 17.7. Arena Pharmaceuticals, Inc.
  • 17.8. AstraZeneca plc
  • 17.9. Bayer AG
  • 17.10. Biogen Inc.
  • 17.11. Boehringer Ingelheim International GmbH
  • 17.12. Bristol Myers Squibb Company
  • 17.13. Celgene Corporation
  • 17.14. Eli Lilly and Company
  • 17.15. Galapagos NV
  • 17.16. Gilead Sciences, Inc.
  • 17.17. GlaxoSmithKline plc
  • 17.18. Janssen Pharmaceuticals, Inc.
  • 17.19. Johnson & Johnson Services, Inc.
  • 17.20. Merck & Co., Inc.
  • 17.21. MorphoSys AG
  • 17.22. Novartis AG
  • 17.23. Pfizer Inc.
  • 17.24. Roche Holding AG
  • 17.25. Sanofi S.A.
  • 17.26. Takeda Pharmaceutical Company Limited
  • 17.27. Theravance Biopharma, Inc.
  • 17.28. UCB S.A.
  • 17.29. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RISANKIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY USTEKINUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CERTOLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MERCAPTOPURINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 179. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 182. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 208. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 210. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 212. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 222. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY CLASS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THIOPURINES, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)